M&A / Deals Roche doubles down on BTK with $2.3bn Nurix deal PharmaphorumRoche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.HematologyRead full story pharminent June 8, 2026 (Last updated: June 8, 2026) Pharmaphorum Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly and Novo face off at ADA 2026 as others seek to compete in obesityNext: Incyte gobbles up Star’s Vega haematology unit in $2bn deal Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
